Impact Biomedical (NYSEAMERICAN:IBO – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.08) EPS for the quarter, FiscalAI reports. Impact Biomedical had a net margin of 2,254.28% and a return on equity of 8.81%. The firm had revenue of $0.02 million for the quarter.
Impact Biomedical Stock Up 5.6%
NYSEAMERICAN IBO opened at $4.33 on Tuesday. Impact Biomedical has a 52 week low of $2.43 and a 52 week high of $10.47. The firm’s 50-day simple moving average is $4.98 and its two-hundred day simple moving average is $6.19.
Impact Biomedical Company Profile
Impact BioMedical, Inc is a biotechnology company focused on developing biomedical technologies and products intended to address public-health and healthcare needs. Its activities have included research into antiviral, antimicrobial, immunomodulatory and other therapeutic applications.
The company has been associated with the development of Equivir, an antiviral technology described as having potential broad-spectrum applications. Impact BioMedical has also pursued intellectual property and product-development opportunities in areas such as infectious disease prevention, immune support and related biomedical solutions.
Impact BioMedical is affiliated with DSS, Inc, a diversified holding company with interests in healthcare and other industries.
Read More
- Five stocks we like better than Impact Biomedical
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Impact Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impact Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
